Skip to Main Content

REPRESENTATIVE EXPERIENCE

Billy M.C. Chen

Served as issuer's counsel to StemCyte International, Ltd. (TPEX: 4178), a leading regenerative cell therapy company, in its initial public offering and primary listing on the Taiwan Stock Exchange.
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel